0R15 11395.0 -4.4043% 0R1E 9100.0 1.1111% 0M69 None None% 0R2V 237.0 2.5974% 0QYR 1354.0 2.9266% 0QYP 457.0 0.3293% 0RUK None None% 0RYA 1460.0 1.2483% 0RIH 187.4 -0.213% 0RIH 187.4 -0.213% 0R1O 197.0 9862.0733% 0R1O None None% 0QFP None None% 0M2Z 290.0 0.6071% 0VSO 28.5 -19.9551% 0R1I None None% 0QZI 504.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 172.35 -89.9621%

Embecta Corp

Healthcare US EMBC

12.78USD
-0.39(2.96%)

Last update at 2024-07-15T14:47:00Z

Day Range

12.7113.10
LowHigh

52 Week Range

9.8127.29
LowHigh

Fundamentals

  • Previous Close 13.17
  • Market Cap754.90M
  • Volume74409
  • P/E Ratio10.73
  • Dividend Yield4.57%
  • EBITDA223.00M
  • Revenue TTM1132.50M
  • Revenue Per Share TTM19.71
  • Gross Profit TTM 774.90M
  • Diluted EPS TTM1.22

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax 105.70M 256.60M 495.00M 485.80M 500.00M
Minority interest - - - - -
Net income 70.40M 223.60M 415.00M 427.60M 432.00M
Selling general administrative 341.30M 294.80M 240.00M 0.30M 222.00M
Selling and marketing expenses - - 240.00M 215.00M 222.00M
Gross profit 749.90M 774.90M 800.00M 762.60M 786.00M
Reconciled depreciation 32.60M 31.70M 38.00M 38.00M 36.00M
Ebit 215.20M 309.60M 492.00M 486.50M 502.00M
Ebitda 247.80M 393.40M 530.00M 524.10M 538.00M
Depreciation and amortization 32.60M 83.80M 38.00M 37.60M 36.00M
Non operating income net other - -6.80000M - - -
Operating income 221.50M 309.60M 492.00M 486.50M 502.00M
Other operating expenses 896.80M 761.00M 673.00M 599.00M 607.00M
Interest expense 107.00M 46.20M 3.00M 0.00000M 2.00M
Tax provision 35.30M 33.00M 80.00M 58.00M 68.00M
Interest income - - - - -
Net interest income -107.00000M -46.20000M - 0.00000M -
Extraordinary items - - - - -
Non recurring - 58.90M - - -
Other items - - - - -
Income tax expense 35.30M 33.00M 80.00M 58.20M 68.00M
Total revenue 1120.80M 1129.50M 1165.00M 1085.50M 1109.00M
Total operating expenses 525.90M 406.40M 308.00M 276.10M 284.00M
Cost of revenue 370.90M 354.60M 365.00M 322.90M 323.00M
Total other income expense net -11.30000M -53.00000M 3.00M -0.70000M -2.00000M
Discontinued operations - - - - -
Net income from continuing ops 70.40M 223.60M 415.00M 428.00M 432.00M
Net income applicable to common shares - 223.60M 415.00M 428.00M 432.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 1214.40M 1086.40M 788.00M 738.00M -
Intangible assets - 8.90M 18.00M 14.00M -
Earning assets - - - - -
Other current assets 111.40M 306.00M 23.00M 13.00M -
Total liab 2036.10M 1977.80M 194.00M 166.00M -
Total stockholder equity -821.70000M -891.40000M 594.00M 572.00M -
Deferred long term liab - 46.10M - - -
Other current liab 286.90M 246.50M 110.00M 87.00M -
Common stock 0.60M 0.60M 865.00M 834.00M 855.00M
Capital stock 0.60M 0.60M 865.00M 834.00M -
Retained earnings -541.10000M -577.10000M - - -
Other liab - 41.80M 27.00M 25.00M 42.00M
Good will - 15.70M 16.00M 16.00M -
Other assets - 89.20M 7.00M 6.00M 8.00M
Cash 326.50M 330.90M - - -
Cash and equivalents - - - - -
Total current liabilities 353.50M 301.00M 164.00M 137.00M 126.00M
Current deferred revenue - - - - -
Net debt 1312.00M 1312.90M - - -
Short term debt 13.10M 13.10M - - -
Short long term debt 9.50M 9.50M - - -
Short long term debt total 1638.50M 1643.80M - - -
Other stockholder equity 27.90M 10.00M -271.00000M -262.00000M -278.00000M
Property plant equipment - 307.90M 455.00M 467.00M 457.00M
Total current assets 749.10M 664.70M 292.00M 235.00M 248.00M
Long term investments - - - - -
Net tangible assets - -883.40000M 560.00M 542.00M 545.00M
Short term investments - - - - -
Net receivables 159.10M 133.10M 151.00M 120.00M 127.00M
Long term debt 1593.90M 1598.10M - - -
Inventory 152.10M 122.80M 118.00M 102.00M 101.00M
Accounts payable 53.50M 41.40M 54.00M 50.00M 47.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -309.10000M -324.90000M -271.00000M -262.00000M -
Additional paid in capital - - - - -
Common stock total equity - 0.60M - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -577.10000M - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 140.40M 95.50M 11.00M 11.00M -
Deferred long term asset charges - - - - -
Non current assets total 465.30M 421.70M 496.00M 503.00M -
Capital lease obligations 35.10M 36.20M - - -
Long term debt total - 1598.10M - - -
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -26.50000M -24.00000M -39.00000M -42.00000M -69.00000M
Change to liabilities - 83.60M 30.00M -4.00000M 32.00M
Total cashflows from investing activities - -24.00000M -39.00000M -42.00000M -69.00000M
Net borrowings - 1411.90M 1443.40M 1443.40M 1443.40M
Total cash from financing activities -48.70000M -48.00000M -417.00000M -456.60000M -436.00000M
Change to operating activities - -90.50000M -12.00000M 15.00M -9.00000M
Net income 70.40M 223.60M 415.00M 427.60M 432.00M
Change in cash -4.40000M 330.90M -417.00000M -457.00000M -436.00000M
Begin period cash flow 330.90M 0.00000M 0.00000M 0.00000M 0.00000M
End period cash flow 326.50M 330.90M 0.00000M 0.00000M 0.00000M
Total cash from operating activities 67.70M 412.20M 456.00M 498.50M 505.00M
Issuance of capital stock - - - - -
Depreciation 32.60M 31.70M 38.00M 38.30M 36.00M
Other cashflows from investing activities - -0.40000M - - -
Dividends paid 34.40M 8.60M 8.60M 8.60M 8.60M
Change to inventory -28.80000M -23.40000M -18.00000M 3.50M 9.00M
Change to account receivables 7.00M 122.70M -32.00000M -2.40000M -10.00000M
Sale purchase of stock - - - - -
Other cashflows from financing activities -3.60000M -32.80000M -417.00000M -456.60000M -436.00000M
Change to netincome - 51.10M 35.00M 20.00M 15.00M
Capital expenditures 26.50M 24.00M 39.00M 41.90M 69.00M
Change receivables - 122.70M - - -
Cash flows other operating - -80.30000M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 340.20M - - -
Change in working capital -80.00000M 92.40M -32.00000M 12.70M 22.00M
Stock based compensation 21.50M 18.70M 13.00M 12.70M 12.00M
Other non cash items 8.90M 72.30M 24.00M 9.40M 9.00M
Free cash flow 41.20M 388.20M 417.00M 456.60M 436.00M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EMBC
Embecta Corp
-0.39 2.96% 12.78 10.73 - 0.53 2.61 1.72 9.29
ISRG
Intuitive Surgical Inc
-4.33 0.97% 439.83 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA
-1.56 1.41% 109.05 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme
4.24 1.97% 219.16 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company
-1.66 0.72% 227.45 47.65 17.51 3.60 2.69 4.33 19.06

Reports Covered

Stock Research & News

Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Embecta Corp

300 Kimball Drive, Parsippany, NJ, United States, 07054

Key Executives

Name Title Year Born
Mr. Devdatt Kurdikar Pres, CEO & Director 1969
Mr. Jacob P. Elguicze Sr. VP & CFO 1973
Mr. Jeffrey Z. Mann Sr. VP, Gen. Counsel, Head of Corp. Devel. & Corp. Sec. 1973
Mr. Ajay Kumar Sr. VP & Chief HR Officer 1971
Mr. Shaun Curtis Sr. VP of Global Manufacturing & Supply Chain 1970
Mr. Brian R. Capone VP, Chief Accounting Officer & Corp. Controller 1975
Ms. Colleen Riley Sr. VP & Chief Technology Officer 1965
Ms. Ginny Blocki Sr. VP of Global Marketing & Product Management NA
Mr. Tom Blount Sr. VP & Pres of North America 1974
Mr. Slobodan Radumilo Sr. VP & Pres of International 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions